Increased growth and yield of green lettuce (Lactuca Sativa L.) using inorganic fertiliser types.

Green lettuce (Lactuca sativa L.) is a popular leafy vegetable grown and consumed worldwide for its crisp texture and nutritional value. This study investigates the impact of different inorganic fertilizers on the growth and productivity of green lettuce, with the aim of determining the most effective fertilizers for producing vibrant green lettuce. The research was carried out at the Jaya Wijaya Research Centre, Faculty of Agriculture, Slamet Riyadi University, employing a randomized design with a single factor: the type of inorganic fertilizer. The experimental treatments included Nutrimax, NPK 25.7.7, and a control group, each replicated four times. Lettuce plants treated with Nutrimax exhibited superior performance across various metrics, including plant height (32.63 cm), leaf color intensity (3.25), leaf count (13.5 leaves), fresh weight (94.75 grams), and dry weight (5.33 grams). Statistical analysis using Analysis of Variance, followed by the Least Significant Difference test at a significance level of 5%, revealed a significant influence of fertilizer treatment on the growth and yield of green lettuce plants. The type of fertilizer applied significantly affected the growth and yield of green lettuce cultivated using a floating hydroponic system. The number of leaves on the plant directly impacted the fresh weight of the leafy vegetables. These findings can serve as a valuable guide for optimizing green lettuce cultivation practices to achieve maximum yields.

Tamoxifen in men: a review of adverse events.

Tamoxifen is an off-label option to treat men for breast cancer, infertility, and idiopathic gynecomastia. Lately, tamoxifen has been proposed as a treatment to prevent gynecomastia in prostate cancer patients receiving antiandrogen therapy. We reviewed the adverse events (AEs) reported in studies of men prescribed tamoxifen for these conditions to better understand its side-effect profile. We searched PubMed for randomized controlled trials (RCTs) that included safety data of tamoxifen treatment in men with prostate cancer, breast cancer, infertility, and idiopathic gynecomastia. Non-RCTs were also reviewed. The results demonstrate that the AE profile in tamoxifen-treated male populations varied. Excluding breast events, gastrointestinal, and cardiovascular problems were the most commonly reported AEs in prostate cancer patients, whereas more psychiatric disorders were reported in male breast cancer patients. Few AEs have been documented in men receiving tamoxifen for infertility and idiopathic gynecomastia. Less than 5% of men withdrew from tamoxifen therapy because of toxicity. This suggests that for most men, tamoxifen is well-tolerated. Of those who discontinued tamoxifen, the majority were male breast cancer patients, and cardiovascular events were the most common reason for stopping tamoxifen treatment. Unfortunately, in many cases, the reasons for withdrawing tamoxifen were unspecified. Based on the available evidence, tamoxifen's AE profile appears to vary depending upon which male population is treated. Also, the frequency at which AEs occur varies - less AEs in men with infertility and idiopathic gynecomastia compared to men with prostate cancer or breast cancer. Long-term studies that rigorously document the side-effect profile of tamoxifen in men are lacking.